translocations or amplifications in addition to the genomic alterations by now existing in the initial CLL, but lack the common mutations observed in Major DLBCL indicating they might correspond to a unique Organic group.gene in people relapsing just after therapy Using the BCL2 antagonist venetoclax. 66 Resistance to those agents has been associat